-
公开(公告)号:US20190337961A1
公开(公告)日:2019-11-07
申请号:US16465156
申请日:2017-12-15
发明人: Michael Miller , Harry R. Chobanian , Shuwen He , Jinsong Hao , Barbara Pio , Yan Guo , Dong Xiao
IPC分类号: C07D491/107 , C07D311/96 , C07D405/12 , A61P3/10
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US20160280626A1
公开(公告)日:2016-09-29
申请号:US15034189
申请日:2014-12-01
发明人: Thomas Bara , Harry R. Chobanian , Yan Guo , Hubert Josien , Michael Miller , Barbara Pio , Christopher W. Plummer , Cangming Yang , Dong Xiao
IPC分类号: C07C59/72 , C07D213/64 , A61K31/44 , C07D209/08 , A61K31/404 , C07D231/12 , A61K31/415 , C07D417/04 , A61K31/427 , C07D471/04 , A61K31/437 , C07D249/04 , A61K31/4192 , C07D333/24 , A61K31/381 , C07C255/59 , A61K31/277 , C07D221/04 , A61K31/435 , A61K45/06 , A61K31/192
CPC分类号: C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US20160009696A1
公开(公告)日:2016-01-14
申请号:US14772290
申请日:2014-02-27
申请人: Michael MILLER , Kallol BASU , Duane DEMONG , Jack SCOTT , Wei LI , Joel HARRIS , Andrew STAMFORD , Marc POIRIER , Paul TEMPEST , MERCK SHARP & DOHME CORP.
发明人: Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Wei Li , Joel Harris , Andrew Stamford , Marc Poirier , Paul Tempest
IPC分类号: C07D403/14 , C07D401/14 , C07D491/107 , C07D417/14 , C07D471/10 , C07D413/14 , C07D498/08
CPC分类号: C07D403/14 , A61K31/505 , A61K31/506 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/10 , C07D491/107 , C07D498/08
摘要: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
-
公开(公告)号:US11180504B2
公开(公告)日:2021-11-23
申请号:US16083980
申请日:2017-03-15
发明人: Gopalan Balasubramanian , Maneesh Paul-Satyaseela , Chidambaram Venkateswaran Srinivasan , Sridhar Ramanathan Iyer , Hariharan Periasamy , Venkatesan Parameswaran , Bharani Thirunavukkarasu , Prabhakar Rao Gunturu , Manjula Devi Deshkumar , Venkateshwarlu Jakkala , Michael Miller , Ravi P. Nargund , Sheo Singh , Shuzhi Dong , Hongwu Wang , Katherine Young
IPC分类号: A61K31/407 , C07D487/04 , C07D519/00
摘要: This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R1, and R4 are as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.
-
公开(公告)号:US10968193B2
公开(公告)日:2021-04-06
申请号:US15328735
申请日:2015-08-06
发明人: Helen Chen , Steven L. Colletti , Duane DeMong , Yan Guo , Michael Miller , Anilkumar Nair , Christopher W. Plummer , Dong Xiao , De-Yi Yang
IPC分类号: C07D491/06 , C07D311/60 , C07D405/14 , C07D491/08 , C07D405/10 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/107 , A61K31/4985 , C07D451/02 , A61K31/397 , A61K45/06 , A61K31/366 , C07D413/14 , C07D413/12 , C07D471/08
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US20190071412A1
公开(公告)日:2019-03-07
申请号:US16083677
申请日:2017-03-24
发明人: Michael Miller , Harry R. Chobanian
IPC分类号: C07D401/04 , A61K45/06 , A61K31/4725 , C07D413/04 , A61K31/538 , A61K31/4709 , C07D215/14 , A61K31/47 , C07D265/36
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US09957219B2
公开(公告)日:2018-05-01
申请号:US15034189
申请日:2014-12-01
发明人: Thomas Bara , Harry R. Chobanian , Yan Guo , Hubert Josien , Michael Miller , Barbara Pio , Christopher W. Plummer , Cangming Yang , Dong Xiao
IPC分类号: C07C59/72 , A61K45/06 , A61K31/192 , A61K31/404 , A61K31/435 , C07D221/04 , C07D231/12 , C07D207/333 , C07D277/42 , C07D209/12 , A61K31/277 , A61K31/381 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/437 , A61K31/44 , C07C255/59 , C07D209/08 , C07D213/64 , C07D249/04 , C07D333/24 , C07D417/04 , C07D471/04
CPC分类号: C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US09840512B2
公开(公告)日:2017-12-12
申请号:US14767815
申请日:2014-02-20
发明人: Linda L. Brockunier , Helen Chen , Harry R. Chobanian , Matthew J. H. Clements , Alejandro Crespo , Duane E. DeMong , Yan Guo , William K. Hagmann , Karen M. Marcantonio , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao
IPC分类号: C07D311/04 , C07D311/28 , C07D491/052 , C07D493/04 , C07D201/00 , C07D405/14 , C07D319/20 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/10 , C07D417/04 , C07D491/048 , A61K31/352 , A61K31/416 , A61K31/422 , A61K31/427 , A61K31/436 , A61K31/4433 , A61K31/444 , A61K31/497 , A61K31/538 , A61K45/06
CPC分类号: C07D493/04 , A61K31/352 , A61K31/416 , A61K31/422 , A61K31/427 , A61K31/436 , A61K31/4433 , A61K31/444 , A61K31/497 , A61K31/538 , A61K45/06 , C07D201/00 , C07D311/04 , C07D311/28 , C07D319/20 , C07D405/04 , C07D405/06 , C07D405/10 , C07D405/14 , C07D413/10 , C07D417/04 , C07D491/048 , C07D491/052
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US09718818B2
公开(公告)日:2017-08-01
申请号:US14912761
申请日:2014-08-18
申请人: MERCK SHARP & DOHME CORP. , Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
发明人: Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
IPC分类号: A61K31/44 , C07D471/04 , C07D498/04 , C07D519/00 , C07D487/04
CPC分类号: C07D471/04 , C07D487/04 , C07D498/04 , C07D519/00
摘要: The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
-
公开(公告)号:US09688654B2
公开(公告)日:2017-06-27
申请号:US14772525
申请日:2014-02-27
发明人: Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Hong Liu , Xing Dai , Andrew Stamford , Marc Poirier , Paul Tempest
IPC分类号: C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D491/08 , C07D495/08 , C07D498/04 , C07D498/08
CPC分类号: C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D491/08 , C07D495/08 , C07D498/04 , C07D498/08
摘要: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
-
-
-
-
-
-
-
-
-